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AbstrACt
Objectives Recent evidence has highlighted the high 
prevalence and impact of multimorbidity, but the evidence 
base for improving management is limited. We have tested 
a new complex intervention for multimorbidity (the 3D 
model). The paper describes the baseline characteristics 
of practices and patients in order to establish the external 
validity of trial participants. It also explores current ‘usual 
primary care’ for multimorbidity, against which the 3D 
intervention was tested.
Design Analysis of baseline data from patients in a 
cluster-randomised controlled trial and additional data 
from practice staff.
setting Primary care in the UK.
Participants Patients with multimorbidity (n=5253) and 
154 practice staff.
Primary and secondary outcome measures Using 
surveys and routinely available data, we compared the 
characteristics of participating and non-participating 
practices and participating and non-participating eligible 
patients. Baseline questionnaire data from patient 
participants was used to examine participant illness 
burden, treatment burden and perceptions of receiving 
patient-centred care. We obtained data about usual care 
preintervention from practice staff using questionnaires 
and a structured pro forma.
results Participating practices were slightly larger, in less 
deprived areas, and with slightly higher scores for patient 
satisfaction compared with non-participating practices. 
Patients with dementia or learning difficulties were 
likely to be excluded by their general practitioners, but 
comparison of participants with non-participants identified 
only minor differences in characteristics, suggesting 
that the sample was otherwise representative. Patients 
reported substantial illness burden, and an important 
minority reported high treatment burden. Although patients 
reported relatively high levels of satisfaction with care, 
many reported not having received potentially important 
components of care.
Conclusion This trial achieved good levels of external 
validity. Although patients were generally satisfied 
with primary care services, there was significant 
room for improvement in important aspects of care for 
multimorbidity that are targeted by the 3D intervention.
trial registration number ISRCTN06180958; Post-
results.
IntrODuCtIOn 
Recent evidence has highlighted the impor-
tance of multimorbidity for current health 
policy.1 Multimorbidity among long-term 
conditions is the norm among older patients, 
and is common at a younger age in deprived 
populations.2 3 It is associated with signifi-
cant impacts on quality of life, mortality and 
healthcare utilisation.1 
There is increasing consensus on the sort of 
care that is required for the management of 
patients with multimorbidity.1 4 5 Much of this 
derives from consensus about high-quality 
care for long-term conditions more gener-
ally, with a focus on care planning, shared 
decision-making and self-management.1 6–8 
However, management of patients with multi-
morbidity also raises specific challenges, such 
as how to prioritise among conditions and 
how best to manage the treatment burden 
experienced due to multiple treatments and 
multiple appointments.7 9 The increased 
prevalence of depression in multimorbidity is 
strengths and limitations of this study
 ► Data on the external validity of trial populations are 
often not available, but recruitment using routine 
general practitioner records allowed us to compare 
participants and non-participants.
 ► We collected detailed data on care for multimorbid-
ity using validated scales, complemented with data 
from staff for a more comprehensive assessment.
 ► Comparisons of participants and non-participants 
were limited to data available in routine records.
 ► Data on delivery and quality of care were generally 
based on patient and clinician self-report.
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well recognised, and comorbid depression is associated 
with worse outcomes.10
However, the evidence base for the management of 
multimorbidity remains sparse. A recent Cochrane review 
reported only 18 randomised trials specifically targeting 
multimorbidity, and concluded that ‘there are remaining 
uncertainties about the effectiveness of interventions for 
people with multimorbidity in general due to the rela-
tively small number of RCTs conducted in this area to 
date.6 11 The National Institute for Health and Care Excel-
lence (the leading UK organisation for the development 
of clinical guidelines) has published guidelines for the 
clinical assessment and management of multimorbidity, 
reviewing the evidence for varying ‘format of encounters’ 
in people with multimorbidity (including longer consul-
tations, structured recall, involving the patient in agen-
da-setting and multiprofessional appointments) and for 
primary care-based comprehensive geriatric assessment.1 
However, the evidence available did not support any 
specific recommendation on how to organise primary care 
to better meet the needs of people with multimorbidity. 
Instead the guideline development group recommended 
that trials were needed evaluating new organisational 
approaches for people with multimorbidity.
The Cochrane review suggested that, given the 
complexity of needs and management of patients with 
multimorbidity, interventions are likely to be ‘complex’ 
(ie, ‘involving several components acting in concert 
to improve care’).6 11 Our team has developed the 
3D model for the management of multimorbidity in 
primary care. The model is described in full elsewhere,12 
and has recently undergone evaluation in a large-scale 
randomised controlled trial with concurrent economic 
and process evaluation.12 13
Key problems posed by current healthcare organisation 
and experienced by patients with multimorbidity are a lack 
of holistic patient-centred care, a high burden of illness 
and a high level of treatment burden due to multiple 
medications and the need to attend numerous appoint-
ments. Figure 1 shows how the 3D approach addresses 
these problems. The basis for 3D is the patient-centred 
care model5 14 15 which includes four components:
 ► A focus on the patient’s individual disease and illness 
experience.
 ► A biopsychosocial perspective.
 ► Finding common ground on what the problem is and 
mutually agreeing management plans.
 ► Enhancing the relationship between the patient and 
doctor (the therapeutic alliance).
The Medical Research Council has a well-developed 
framework for the development, evaluation and descrip-
tion of complex interventions.16 Recent work in this area 
has also emphasised two additional issues. First, there is 
a need to understand the practice and patient popula-
tions who actually enter trials of complex interventions, 
compared with those who are potentially eligible, to better 
Figure 1 3D logic model including theoretical mechanisms of action. GP, general practitioner; LTCs, long-term conditions; 
QOL, quality of life.
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understand the external validity of the study.17 18 Second, 
there is a need to better understand the comparator 
to the intervention (in this case, ‘usual primary care’) 
in order to understand the content and quality of care 
against which the complex intervention is being tested.19 
The aims of this study are therefore to:
1. Compare practices and patients participating in the tri-
al with non-participants.
2. Describe the characteristics of participating patients 
at baseline in terms of their experiences of (a) illness 
burden (b) treatment burden and (c) patient-centred 
care.
3. Describe usual care for people with multimorbidity.
MethODs
Design
The design of the 3D trial and process evaluation has 
been described in full12 13 and is briefly summarised 
here. The 3D trial is a multicentre pragmatic, two-arm, 
practice-level cluster-randomised controlled trial. In the 
UK, each patient is registered to receive free healthcare 
under the National Health Service (NHS) from one 
local general practice. For most patients, chronic disease 
management is provided by general practitioners (GPs) 
and nurses within their registered practice with little or 
no involvement from hospital specialists. Practices are 
incentivised to provide high-quality care for many spec-
ified chronic diseases by the NHS Quality and Outcomes 
Framework (QOF) pay-for-performance scheme.20
The 3D study is based in general practices in three 
areas: Bristol and Greater Manchester in England and 
Ayrshire in Scotland. Volunteer practices were recruited 
from areas with a range of socioeconomic character-
istics. For inclusion practices had to have at least 2 GPs 
and 4500 registered patients and to use the EMIS clinical 
IT system (used by the majority of practices in the UK). 
Inclusion criteria for patients were age 18+ and having 
three or more types of long-term condition from those 
included in the QOF (online supplementary appendix 
A). We decided to include patients with three or more 
(rather than two or more) conditions in order to focus 
effort on more complex patients who may have more to 
gain from a new model of organisation. Up to 150 poten-
tially eligible patients were randomly selected from each 
practice by a researcher using a random number func-
tion in Microsoft Excel, and using an anonymous patient 
identifier. Selected patients’ notes were screened by their 
GPs against the following exclusion criteria: having a 
life expectancy of less than 12 months; serious suicidal 
risk; known to be leaving the practice within 12 months; 
unable to complete questionnaires in English even with 
the help of carers; actively taking part in other research 
involving extra visits to primary care or other health 
services; lacking capacity to consent (Scotland only) 
or being considered unsuitable for the research study 
by their GP. All remaining patients were sent an invita-
tion from their practice including information about 
the study, a consent form and baseline questionnaire. 
Patients self-consented by returning the consent form 
and completed baseline questionnaire to the research 
team, using a freepost envelope. Non-respondents were 
sent one postal reminder 10–14 days later, supplemented 
by a telephone reminder in those practices where recruit-
ment targets were not met.
Patient data
We had data on two groups of patients. For patients who 
were invited to the trial (‘potentially eligible patients’), 
we had data on age, sex and QOF-recorded conditions.
For eligible patients who consented to take part 
(‘participating patients’), data were also avail-
able from the baseline questionnaire measuring 
depression (Hospital Anxiety and Depression 
Scale, HADS),21 quality of life (EQ5D-5L),22 illness 
burden (Bayliss et al),23 treatment burden Multimor-
bidity Treatment Burden Questionnaire (MTBQ),24 
patients’ perception of the quality of chronic illness 
care (Patient Assessment of Care in Chronic Illness 
Care (PACIC))25 and perceived empathy of GPs and 
nurses (Consultation and Relational Empathy (CARE) 
measure).26
The patient questionnaire included several questions 
about holistic patient-centred care. These included the 
PACIC measure and the CARE measure, along with two 
questions from the Long-Term Conditions 6 (LTC6) 
questionnaire.27 Three further questions were included 
regarding satisfaction with current care, whether 
patients usually saw their preferred GP, and whether 
they had a written care plan (all based on the national 
GP Patient Survey).28
staff perceptions and practice data on the organisation of 
care
At the start of the trial, participating GPs and practice 
nurses completed a purpose-designed questionnaire 
about their beliefs and attitudes regarding care of 
patients with multimorbidity. Researchers training the 
nurses and GPs in intervention practices asked them to 
complete the questionnaire before the training began. 
In usual care practices, the questionnaire was distrib-
uted via the practice manager and followed up with one 
researcher reminder where there was a poor response. 
The questionnaire consisted of 12 statements that 
were scored from 1 (‘strongly disagree’) to 5 (‘strongly 
agree’) (online supplementary appendix B). Only 
those questions which can be compared with patient’s 
perspectives have been reported.
In addition, information about how the practice 
organised usual care for patients with long-term condi-
tions  was collected from all practices through a struc-
tured pro forma completed by a single key respondent 
in each practice (usually the practice manager) via an 
emailed survey supplemented by telephone or face-to-
face interview. This covered staff resources, organisa-
tion of long-term condition review clinics and practice 
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policy on medication reviews, care plans and continuity 
of care.
Analysis
In order to compare practices and patients partici-
pating in the trial with non-participants, we compared 
the characteristics of practices in the 3D trial with prac-
tices in the same Clinical Commissioning Group and 
national data. We assessed differences in patient popu-
lations (age, deprivation), practice size and published 
assessments of quality (the percentage of targets met 
within the QOF)29 and patient satisfaction (based on 
the national GP Patient Survey).28
We described the demographic and clinical char-
acteristics of patients at each stage of recruitment 
to 3D—those identified as potentially eligible but 
excluded by their GP, those eligible but not partici-
pating (due to non-response or actively declining), 
and those who agreed to participate in the study. All 
comparisons were analysed in multilevel regression 
models which included practice as a random effect. For 
participants in the trial, we present descriptive data on 
patients self-reported baseline measures of their illness 
burden and treatment burden. Because the number of 
potential participants is large (n=5253), we have inter-
preted whether absolute differences are meaningful 
rather than relying only on p values (since even small 
and non-meaningful differences will generate small p 
values with large samples).
To describe the extent to which current care for 
people with multimorbidity is patient centred from the 
perspective of patients we present participant responses 
to individual question items from the baseline patient 
questionnaire reflecting key concepts in patient-cen-
tred care.
We also provide data about staff views about care for 
people with multimorbidity and report descriptive data 
from the structured pro forma about usual care for 
patients with multimorbidity in all practices participating 
in the trial.
For all descriptive analyses we have calculated intra-
cluster correlation coefficients (ICCs) to demonstrate 
the extent of practice-level variability. All analyses were 
performed using Stata V.15 (StataCorp).
Patient and public involvement
An active group of up to 14 patients and carers provided 
a service user perspective. Through regular meetings 
with the research team, they contributed to refinement 
of the research questions and design of the intervention. 
The group were consulted about the perceived burden 
of the intervention, and provided valuable feedback 
on the specific outcome measures chosen including 
helping to develop the measure of treatment burden. 
They particularly contributed to communications with 
participants in recruitment materials and regular news-
letters about progress. The findings will be available to 
participants and the public on the trial website.
results
What types of practices and patients participated in the 3D 
trial, and how did they compare to non-participants?
Across the three sites, 68 practices expressed initial 
interest in the study, of which 35 signed up to the study. 
Two practices subsequently withdrew prior to rando-
misation. The remaining 33 practices (49% of those 
expressing interest) were randomised, 16 into the inter-
vention arm and 17 to usual care. Descriptive character-
istics of the 33 practices are shown in table 1. Compared 
with all practices in their local area, practices which 
agreed to participate tended to be slightly larger, in 
less deprived areas and had slightly higher scores for 
patient satisfaction (table 1).
The flow of patients into the trial is shown in figure 2. 
Between 20 May 2015 and 31 December 2015, a total 
of 9772 patients were identified as potentially eligible, 
representing 3.9% of the adult population. Of these, 
5253 were randomly sampled from practice registers. 
GPs excluded 575 (11%) of those based on medical 
record data because they were ineligible or the GP felt 
it would be inappropriate to invite them to participate. 
Potential participants who were excluded by their GPs 
were more likely to have dementia or learning difficulties 
and less likely to have diabetes or respiratory conditions 
than those not excluded (table 2). There was consider-
able variation between practices in the percentage of 
patients excluded (mean=11.01%, SD=8.01%).
Of 4678 patients invited to participate, 1546 (33%) 
provided consent. Differences between participants and 
non-participants in terms of their health conditions 
were small, except that participants were less likely to 
have dementia than non-participants. Of the 11 types 
of long-term condition, which made people eligible 
for the trial the most commonly reported were cardio-
vascular disease (including hypertension, peripheral 
artery disease, chronic kidney disease, coronary heart 
disease and heart failure; affecting 93% of participants), 
diabetes (52%) and respiratory conditions (asthma or 
chronic obstructive pulmonary disease; 50%).
Baseline demographic and health data on excluded 
patients, non-participants and participants are shown 
in table 2. Excluded patients were more likely to be 
female, older and have four or more conditions than 
those invited. Participants and non-participants had 
very similar demographic characteristics and experi-
enced a similar number of health conditions.
Two-thirds of patients (66%) reported having fair or 
poor health, with less than 7% reporting very good or 
excellent health (table 3). Although inclusion to the 
trial was based on QOF conditions in medical records, 
patients self-reported an average of seven conditions 
from the more comprehensive list included in the 
Bayliss measure.23 Based on the HADS measure, more 
than one-third of patients (38%) reported anxiety or 
depression of at least mild severity.
On average, patients reported regularly taking 8 medi-
cations with 32% of patients taking at least 10 regular 
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medications (table 4). More than half (55%) reported 
at least a moderate level of treatment burden, with a 
score of at least 10 on the MTBQ. This score would be 
achieved, for instance, by having some difficulty in at 
least two areas of healthcare, or severe difficulty in at 
least one area.
Table 4 shows that most patients indicated that a GP or 
primary care nurse was responsible for their long-term 
condition, and reported relatively high levels of overall 
satisfaction with their care, although reported levels of 
care coordination were somewhat lower. Three-quarters 
had a preferred GP and of these 66% saw that GP ‘most 
of the time’. In terms of ‘whole person care’, approxi-
mately two-thirds of patients reported that their GP and 
nurse were ‘excellent’ or ‘very good’ at ‘being inter-
ested in them as a whole person’. However, only 37% 
reported that their care was always ‘joined up’.
The data show that many patients do not perceive 
care as patient centred in terms of focusing on an 
individual’s experience and agreeing management 
plans. A relatively high proportion of patients (35%) 
reported ‘rarely’ or ‘not at all’ discussing what was most 
important to them in terms of their health (table 4). 
Only 10% of participants reported having a care plan. 
Scores on the PACIC scale were around the midpoint 
of the scale, with the highest ratings for ‘activation’ and 
‘decision support’, and the lowest for ‘goal setting’ and 
‘follow-up’ (table 4).
the extent to which current care for people with 
multimorbidity is patient centred from the perspective of 
primary care clinicians
The vast majority (88%) of clinicians agreed that patients 
with multimorbidity have a special need for patient-cen-
tred care and over 95% agreed that continuity of care 
improves patient-centred care (table 5). Most clinicians 
agreed that patients with a long-term condition should be 
given a care plan and that they were more likely to adhere 
to goals they had suggested themselves, but were evenly 
divided on whether patients preferred the clinician to 
make the plan. More than half of the clinicians agreed 
that patients’ main concerns may be overlooked in long-
term condition reviews (table 5). Almost all clinicians 
(93%) felt that patients with multimorbidity need longer 
appointments to address all their concerns.
Only 1 of the 33 practices said they routinely provided 
patients with a written care plan (and 80% of the patients 
in that practice said they did not have a written care plan). 
Only one-third (n=10) of practices had an active policy to 
encourage continuity of care, with the majority of others 
saying they try to accommodate patient preference. Only 
36% of practices said they routinely performed depres-
sion screening while 76% said they conducted face-to-face 
medication reviews at least annually. All except two prac-
tices said they tried to combine reviews of some long-term 
conditions which might lessen treatment burden and 
improve joined up care (table 6).
Figure 2 Flow of patients into the 3D trial. GP, general practitioner.
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The ICCs reported in tables 3–6 suggest low levels of 
clustering (ICC <0.05) for all outcomes except for some 
variables relating to practice organisation of care, such 
as whether care is provided mainly by nurses or doctors, 
participant satisfaction with care, and clinicians’ attitudes 
to written care plans.
DIsCussIOn
summary of the findings
The paper describes usual care for people with high levels 
of multimorbidity using baseline data from a cohort of 
patients entering a trial. Comparison of patients entering 
the trial with non-participants identified only minor 
Table 2 Comparison of participating and non-participating patients (long-term conditions on QOF registers, demographic and 
clinical characteristics)*
Excluded†
(n=575)
Non-participants‡ 
(n=3132)
Participants 
(n=1546)
Excluded versus 
invited§¶
Difference between 
participants and non-
participants¶
Dementia 225 (39%) 340 (11%) 60 (4%) OR=0.12, 
p<0.001
−7%
OR=0.32, p<0.001
Depression 246 (43%) 1250 (40%) 559 (36%) OR=0.83, 
p=0.037
−4%
OR=0.87, p=0.037
Severe mental health 
group
47 (8%) 200 (6%) 66 (4%) OR=0.66, 
p=0.014
−2%
OR=0.66, p=0.004
Learning difficulties 48 (8%) 84 (3%) 14 (1%) OR=0.22, 
p<0.001
−2%
OR=0.33, p<0.001
Epilepsy 46 (8%) 185 (6%) 76 (5%) OR=0.68, 
p=0.021
−1%
OR=0.81, p=0.128
Diabetes 198 (34%) 1613 (52%) 812 (53%) OR=2.07, 
p<0.001
0%
OR=1.03, p=0.641
Cardiovascular disease 
group**
521 (91%) 2875 (92%) 1445 (93%) OR=1.30, 
p=0.091
+1%
OR=1.25, p=0.066
Stroke or TIA 215 (37%) 1050 (34%) 527 (34%) OR=0.87, 
p=0.124
+1%
OR=1.02, p=0.741
Rheumatoid arthritis 37 (6%) 196 (6%) 103 (7%) OR=0.99, 
p=0.964
+1%
OR=1.06, p=0.631
Respiratory (asthma or 
COPD)
191 (33%) 1456 (46%) 770 (50%) OR=1.87, 
p<0.001
+4%
OR=1.21, p=0.003
Atrial fibrillation 164 (29%) 928 (30%) 530 (34%) OR=1.17, 
p=0.114
+4%
OR=1.19, p=0.009
Male 242 (42%) 1452 (46%) 763 (49%) OR=0.81, 
p=0.018
OR=0.90, p=0.078
Age, mean, (SD), range 77.14 (14.2)
18–106
71.35 (13.4)
20–101
70.79 (11.5)
25–96
β=−6.04, 
p<0.001
β=−1.11, p=0.005
Morbidity count, mean 
(SD), range
3.39 (0.64)
3–6
3.26 (0.53)
3–7
3.23 (0.48)
3–6
β=−0.14,
p<0.001
β=−0.03, p=0.044
Three comorbidities 395 (69%) 2444 (78%) 1234 (80%) OR=1.66, 
p<0.001†† 
OR=1.12, p=0.148†† 
Four comorbidities 140 (24%) 577 (18%) 277 (18%)
Five comorbidities 35 (6%) 99 (3%) 31 (2%)
Six comorbidities 5 (1%) 11 (0.4%) 4 (0.3%)
Seven comorbidities 1 (0.03%)
Baseline characteristics of participating patients in terms of (1) illness burden and (2) treatment burden.
*Since an inclusion criterion was having three or more conditions, the percentages in each column exceed 100%.
†Eligible on record search but excluded by GP before invitation.
‡Non-participants combine patients who declined and those who did not respond.
§Invited includes non-participants and participants combined.
¶ORs were calculated using a multilevel logistic regression with practice included as a random effect, β coefficients were calculated using a 
multilevel linear regression with practice included as a random effect.
**Includes hypertension, peripheral artery disease, chronic kidney disease, coronary heart disease and/or heart failure.
††3 comorbidities versus 4–7 comorbidities.
COPD, chronic obstructive pulmonary disease; GP, general practitioner; QOF, Quality and Outcomes Framework; TIA, Transient Ischaemic 
Attack. 
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differences in demographic and clinical characteristics, 
suggesting good external validity. As anticipated, partic-
ipants in the trial reported high levels of illness burden 
and treatment burden. Although participants reported 
relatively high levels of satisfaction with their relation-
ships with professionals, responses to specific questions 
identified important gaps in their experience of care as 
patient centred. Although clinicians supported aspects of 
patient-centred care such as continuity of care and care 
plans, and claimed to provide these, the experiences of 
patients were variable. The results of this study suggest 
that there is significant room for improvement in many 
aspects of care for multimorbidity that are targeted by the 
3D intervention. In particular, the results suggest a need 
for improvements in the continuity and coordination of 
care, more focus on the problems which matter most to 
patients (including mental as well as physical health), 
more effort to reduce the burden of treatment and more 
attention to goal setting and sharing written care plans.
strengths and limitations
A key strength of this study was our ability to collect 
comparative data on ‘potentially eligible’ patients, to 
allow us to compare participants and non-participants. 
Data on the external validity of trial populations are often 
not available, but recruitment using routine GP records 
does provide significant advantages in this regard. We 
also collected detailed data on care for multimorbidity 
using validated scales and complemented these with data 
from staff to provide a more comprehensive assessment.
Detailed comparisons of participants and non-partici-
pants are inevitably difficult because more detailed survey 
data are by definition not available for non-participants, 
and comparisons are restricted to basic demographic 
Table 3 Baseline data on illness and treatment burden (participants)
ICC (95% CI)
Health-related quality of life—
EQ5D (n=1546)
Mean (SD), range −0.51 to 1.00 0.558 (0.287) 0.033
(0.007 to 0.059)
General health (n=1546) Poor 321 (21%) 0.034
(0.008 to 0.060)Fair 681 (45%)
Good 429 (28%)
Very good 88 (6%)
Excellent 5 (0.3%)
Bayliss et al23 Mean count (SD), n, range 1–73 7.5 (3.2), 1543 0.003
(0.000 to 0.014)
Mean illness burden* (SD), n, range 1–26 18.8 (12.4), 1458 0.023
(0.001 to 0.046)
Depression—HADS (n=1512) Normal (0–7) 932 (62%) 0.041
(0.011 to 0.070)Mild (8–10) 285 (19%)
Moderate (11–14) 211 (14%)
Severe (15–21) 84 (6%)
Anxiety—HADS
(n=1506)
Normal (0–7) 964 (64%) 0.029
(0.005 to 0.053)Mild (8–10) 246 (16%)
Moderate (11–14) 204 (14%)
Severe (15–21) 92 (6%)
Mean no of medications (self-
report)
Mean (SD), range 0–34 8.36 (3.94) 0.018
(0.000 to 0.039)
No of medications (n=1396) 0–4 171 (12%) 0.018
(0.000 to 0.039)5–9 781 (56%)
10–14 350 (25%)
15+ 94 (7%)
Multimorbidity Treatment Burden 
Questionnaire (n=1524)
None (0) 308 (20%) 0.026
(0.003 to 0.049)Low (<10) 385 (25%)
Medium (10–22) 425 (28%)
High (≥22) 406 (27%)
*Each self-reported health condition is weighted by the extent to which it affects the participant’s life, from 1 (not at all) to 5 (a lot).
HADS, Hospital Anxiety and Depression Scale; ICC, intracluster correlation coefficient.
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Table 4 Baseline self-reported data on ‘holistic patient-centred care’
Response n(%) or mean (SD)  ICC (95% CI)
Long-term condition care
  Who manages your long-term conditions? 
(n=1436)
GP 920 (64%) 0.036
(0.008 to 0.064)
Nurse 361 (25%) 0.056
(0.019 to 0.093)
Matron 8 (0.6%) 0.001
(0.000 to 0.013)
Hospital doctor 103 (7%) 0.006
(0.000 to 0.021)
Hospital nurse 17 (1%) 0.000
(0.000 to 0.012)
  How satisfied are you with the care you get at 
your GP surgery? (n=1494)
Very dissatisfied 36 (2%) 0.067
(0.026 to 0.108)
Fairly dissatisfied 61 (4%)
Neither 149 (10%)
Fairly satisfied 489 (33%)
Very satisfied 759 (51%)
  Do you think the support and care you receive 
is joined up and working for you? (n=1479)*
Not at all 174 (12%) 0.041
(0.011 to 0.071)
Rarely 165 (11%)
Some of the time 590 (40%)
Always 550 (37%)
  PACIC total (n=1232)† Mean (SD), range 0–5 2.5 (1.0) 0.044
(0.011 to 0.078)
  Patient activation (n=1454)† Mean (SD), range 1–5 3.0 (1.2) 0.041
(0.011 to 0.070)
  Decision support (n=1452)† Mean (SD), range 1–5 2.9 (1.0) 0.029
(0.005 to 0.054)
  Goal setting (n=1443)† Mean (SD), range 1–5 2.3 (1.1) 0.029
(0.004 to 0.053)
  Problem solving (n=1445)† Mean (SD), range 1–5 2.7 (1.2) 0.041
(0.011 to 0.072)
  Follow-up/coordination (n=1432)† Mean (SD), range 1–5 2.2 (1.0) 0.035
(0.007 to 0.062)
Continuity of care
  Do you have a preferred GP? (n=1522) Yes 1148 (75%) 0.038
(0.010 to 0.065)
  If yes, how frequently do you see your preferred 
GP? (n=1141)
Always 508 (44.5%) 0.127
(0.062 to 0.192)
A lot 246 (21.5%)
Some 294 (26%)
Never 81 (7%)
Not tried 8 (0.7%)
  Asked how my consultations with other doctors 
going (n=1399)†
Almost never/generally not
Sometime
Most of time/almost always
888 (63%)
229 (16%)
282 (20%)
0.037
(0.008 to 0.064)
Whole person care
  GP being interested in you as a whole person 
(n=1529)‡
Poor 47 (3%) 0.071
(0.029 to 0.113)
Fair 161 (11%)
Good 284 (19%)
Very good 449 (29%)
Excellent 563 (37%)
  Nurse being interested in you as a whole 
person (n=1295)‡
Poor 22 (2%) 0.027
(0.002 to 0.052)
Fair 99 (8%)
Good 265 (20%)
Very good 390 (30%)
Excellent 453 (35%)
Patient agenda
Continued
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characteristics. However, in this study we have used anony-
mised practice records to compare clinical diagnoses and 
been able to show that participants have similar char-
acteristics to non-participants. The bulk of the findings 
in this study about patient-centred aspects of care come 
from self-report from patients and professionals, and we 
do not know how these relate to actual delivery of care in 
these practices. However, a key aim of the intervention is 
to improve patient experience of care, for which self-re-
port is the optimal assessment method.
As a pragmatic trial, 3D is designed to recruit a popu-
lation with high external validity by ensuring that prac-
tices and patients who participate are representative of 
the wider population to whom the intervention, if effec-
tive, would be provided in real life. The overall response 
rate among patients invited was 33%. This is likely to be 
an underestimate of the proportion of eligible patients 
recruited because some non-responders may not have 
been eligible. Nevertheless, this recruitment rate is typical 
of previous studies in UK populations of primary care 
patients with long-term conditions,30 31 and may be consid-
ered relatively high given that the inclusion criteria for 
this trial selected elderly patients with multiple illnesses.
Our inclusion criteria were based on patients with 3 
or more types of condition from a list of 17 conditions 
included in the QOF framework, a pay-for-performance 
scheme. The use of a wider list of conditions may have led 
to selection of a different group of patients, but we based 
our selection on QOF conditions because they are preva-
lent, clinically important and reliably coded.
Interpretation of the findings and comparisons with the wider 
literature
We raised three main issues in this paper. First, how 
do practices and patients in 3D compare to the wider 
primary care population outside the trial? Although 
limited by available data, the comparisons suggested that 
the consenting sample did not differ markedly from the 
potentially eligible population on measured character-
istics, with the largest difference being the proportion 
with dementia or learning difficulties, which is unsur-
prising given the nature of the recruitment method. We 
sought to ensure that our inclusion criteria were as wide 
as possible, but this study further demonstrates the diffi-
culty of recruiting patients with dementia and learning 
Response n(%) or mean (SD)  ICC (95% CI)
  In the last 12 months did you discuss what was 
most important for you in managing your own 
health? (n=1479)*
Not at all 259 (18%) 0.017
(0.000 to 0.036)
Rarely 251 (17%)
Sometimes 520 (35%)
Always 449 (30%)
  Asked how my long-term condition affects my 
life (n=1412)†
Almost never/generally not
Sometimes
Most of time/almost always
706 (50%)
321 (23%)
385 (27%)
0.036
(0.008 to 0.064)
Care plans
  Do you have a written care plan? (n=1526) No/do not know 1375 (90%) 0.008
(0.000 to 0.023)
Yes 151 (10%)
  I was given copy of my plan (n=1410)† Almost never/generally not
Sometimes
Most of time/almost always
1055 (75%)
131 (9%)
224 (16%)
0.023
(0.000 to 0.045)
  Make a plan that I can do in my daily life 
(n=1425)†
Almost never/generally not
Sometimes
Most of time/almost always
829 (58%)
223 (16%)
373 (26%)
0.027
(0.003 to 0.052)
The extent to which current care for people with multimorbidity is patient centred from the perspective of patients.
*Taken from LTC6 measure. 
†Taken from PACIC measure.
‡Taken from CARE measure.
GP, general practitioner; ICC, intracluster correlation coefficient; LTC6, Long-Term Conditions 6; PACIC, perception of the quality of of chronic illness care. 
Table 4 Continued 
Table 5 Clinicians’ views on care for people with 
multimorbidity (n=154 from 33 practices)
Total ICC (95% CI)
Patients with multimorbidity 
have a special need for 
holistic, patient-centred care
136 (88%) 0.000
(0.000 to 0.116)
Holistic, patient-centred care 
is enhanced by continuity of 
care
148 (96%) 0.000
(0.000 to 0.116)
Patients being reviewed for 
a long-term condition should 
be given a written care plan
96 (62%) 0.188
(0.023 to 0.352)
Patients’ main concerns may 
be overlooked during review 
of long-term conditions
88 (57%) 0.037
(0.000 to 0.165)
Patients with three or more 
conditions need longer 
appointments to address all 
their concerns
143 (93%) 0.040
(0.000 to 0.167)
N (%) of clinicians who agree/strongly agree.
The extent to which current usual care aligns with the 3D model, 
on the basis of practice policies.
ICC, intracluster correlation coefficient.
 o
n
 7 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019845 on 29 August 2018. Downloaded from 
11Chaplin K, et al. BMJ Open 2018;8:e019845. doi:10.1136/bmjopen-2017-019845
Open access
difficulties within trials. Our findings suggest that to 
increase inclusion rates of people with these conditions 
it is important to have strategies to encourage patient 
participation, and to address the reluctance of some 
clinicians to even allow them to be invited to participate. 
Although we cannot be sure that patients agreeing to take 
part do not differ on other important characteristics, the 
data do provide some confidence that the results are not 
based on a highly selected sample, especially in terms of 
physical health conditions.
The second issue is the levels of illness burden, treat-
ment burden and patient-centred care experienced by 
patients with multimorbidity. Our recruitment method 
used a simple method of condition counts which is easy 
to conduct, but it was unclear whether we would iden-
tify patients with high needs. In terms of illness burden, 
our data suggest a sample with relatively high level of 
morbidity and need. Patients report an average of seven 
conditions, and nearly two-thirds report general health 
that is either ‘fair’ or ‘poor’. Patients were receiving a 
large number of medications and more than one-third 
of participants reported anxiety or depression. Exam-
ining the baseline data also demonstrates that, consistent 
with previous literature, patients with multimorbidity are 
burdened by the demands placed on them by treatment 
and expectations of self-management.32 33 Although there 
are many qualitative papers on the experience of patients 
with multimorbidity,34 more quantitative data are needed. 
The trial recruitment procedures therefore identified a 
group of patients with significant burdens of illness and 
treatment whose characteristics seem well matched to 
the intervention model, and where many patients exceed 
minimum requirements of the trial eligibility criteria. Our 
data also suggest that patients do not receive care which 
they perceive as patient centred in several important 
respects, as discussed below.
The third issue raised by this paper is an understanding 
of ‘usual primary care’ for multimorbidity in this popula-
tion, to better understand current practice against which 
the potential benefits of 3D are being assessed. Assessing 
the ‘nature of current care’ for multimorbidity, and the 
degree to which it is ‘patient-centred care’ is a complex 
task. Nevertheless, several important findings can be 
highlighted, linked to the 3D model (figure 1).
Most patients reported satisfaction in general with their 
care. These high ratings are in line with wider work on 
Table 6 Results of practice pro forma at baseline
Question
Yes
N (%) Comments
Is it your policy to encourage 
all patients to see their named 
general practitioner (GP) 
whenever possible?
10 (30) In most practices, patient request and GP availability determined whether they 
saw their usual GP. In most of the 10 practices saying ‘yes’ and in many saying 
‘no’ it was practice policy to fulfil the patient request where possible. However, 
one  practice had a formal personal list system ensuring patients saw their own 
GP.
Is it your policy that every patient 
with a long-term condition (LTC) 
has a face-to-face medication 
review at least once a year?
25 (76) This could be with GP, pharmacist or nurse prescriber.
Is it your policy that every patient 
with ≥2 LTCs receives a written 
care plan?
1 (3) Most practices said they used care plans for some conditions (most commonly 
chronic obstructive pulmonary disease, diabetes, learning disabilities and 
dementia). Other conditions included severe mental health conditions, 
rheumatoid arthritis, various cardiovascular conditions and epilepsy. Only one 
practice said they did not use them for any of the 15 conditions listed and three 
said they only used them for one condition. What practices understood by ‘care 
plan’ varied and some distinguished between care plans and self-management 
plans suggesting that they saw care plans as information primarily for health 
professionals.
Is it your formal policy to annually 
screen for depression all patients 
with ≥2 LTCs who are under 
regular review?
12 (36) For those answering ‘yes’ we checked if they routinely used a formal measure 
such as PHQ2 or PHQ9 for their screening and only counted it as ‘yes’ if they 
did.
Is it your policy to offer combined 
reviews for some patients with 
multimorbidity?
31 (94) 11 practices were offering fully combined reviews which meant they were 
preplanned, encompassing all LTCs, and both clinician and patient were aware 
all conditions were to be reviewed. The other 20 either combined a subset of 
conditions or tried (as far as time and skills allowed) to combine reviews. The 
remaining two were conducting separate reviews.
All answers are reports from the key informant in the practice who was usually a senior administrator or practice manager who could consult 
with clinical colleagues for answers to some questions. Where possible, when there was ambiguity, answers were clarified by follow-up phone 
calls.
PHQ, Patient Health Questionnaire.
 o
n
 7 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019845 on 29 August 2018. Downloaded from 
12 Chaplin K, et al. BMJ Open 2018;8:e019845. doi:10.1136/bmjopen-2017-019845
Open access 
patient perceptions of primary care and might indicate 
limited scope for improvement, but interpretation of 
such satisfaction scores is not always straightforward.35 
However, when considering the more structured aspects 
of care for long-term conditions (as assessed in models 
such as the Chronic Care Model36), the results showed 
more room for improvement. Many patients reported 
that their care was not always joined up and although 
three-quarters of patients in this study had a preferred 
GP, only 59% reported that they usually consult them. 
The 3D model identifies eliciting and responding to the 
patient agenda (their own individual priorities) as a key 
gap in current care, and the questions from the LTC6 
questionnaire and the PACIC scale showed only modest 
levels of agreement about items relating to this facet of 
care. This is in line with previous work in a broader popu-
lation of patients.37 Similarly, despite a very significant 
policy focus on care plans,38 many practices did not have 
a policy to provide them and most patients did not report 
receiving them.
Many of the processes of care where we identified gaps 
(such as improving continuity and coordination of care, 
establishing the patient agenda to improve shared deci-
sion-making, production of care plans,) are a focus of the 
3D model. If these processes are mediators of improve-
ments in quality of life, as hypothesised by the logic 
model underlying the 3D approach, the trial may have 
a reasonable chance of seeing change in the intended 
primary and secondary outcomes, assuming it can be 
implemented.
summary
The data suggest our pragmatic trial has achieved reason-
able levels of external validity, and that the results should 
be generalisable to primary care in the UK. Although 
patients were generally satisfied with their relationships 
with primary care professionals, there remains significant 
room for improvement in important aspects of care for 
multimorbidity that are targeted by the 3D intervention. 
The pragmatic 3D randomised controlled trial will both 
test whether our intervention can generate enhance-
ments in those processes of care, and whether those 
enhancements translate to better patient quality of life, 
patient experience and value for money.
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